Table 1 Baseline characteristics of patients included in the study
Characteristic | Patients receiving 1LOT | Patients receiving 2LOT | Patients receiving 3LOT |
|---|---|---|---|
Number of Patients | 652 | 184 | 18 |
Centre | |||
Cambridge | 228 (35.0%) | 58 (31.5%) | 5 (27.8%) |
Manchester | 424 (65.0%) | 126 (68.5%) | 13 (72.2%) |
Age at index, mean (SD) | 64.84 (10.5) | 62.97 (10.3) | 65.06 (8.9) |
< 70 years, n (%) | 424 (65.0%) | 130 (70.7%) | 13 (72.2%) |
≥ 70 years, n (%) | 228 (35.0%) | 54 (29.4%) | 5 (27.8%) |
Male, n (%) | 426 (65.3%) | 124 (67.4%) | 14 (77.8%) |
Weight (kg), mean (SD) | 78.12 (17.5) | 79.99 (17.8) | 77.92 (12.6) |
Missing, n (%) | 243 (37.3%) | 57 (31.0%) | 6 (33.3%) |
Histological subtype, n (%) | |||
Clear cell | 518 (79.5%) | 141 (76.6%) | 13 (72.2%) |
Non-clear cell | 70 (10.7%) | 28 (15.2%) | 4 (22.2%) |
Other | 22 (3.4%) | 5 (2.7%) | 1 (5.6%) |
MSKCC prognostic risk score (at time of LOT initiation), n(%) | |||
Favourable | 73 (11.2%) | 27 (14.7%) | 2 (11.1%) |
Intermediate | 380 (58.3%) | 77 (41.9%) | 11 (61.1%) |
Poor | 174 (26.7%) | 59 (32.1%) | 2 (11.1%) |
Missing | 25 (3.8%) | 21 (11.4%) | |
Ethnicity, n (%) | |||
White | 629 (96.5%) | 176 (95.7%) | 17 (94.4%) |
Black | 4 (0.6%) | 2 (1.1%) | 0 (0.0%) |
Asian (Chinese/other) | 1 (0.2%) | 1 (0.5%) | 0 (0.0%) |
Asian (South-East Asian) | 15 (2.3%) | 5 (2.7%) | 1 (5.6%) |
Mixed | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Other | 3 (0.5%) | 0 (0.0%) | 0 (0.0%) |
Comorbidity (History of), n (%) | |||
Hypertension | 200 (30.7%) | 55 (29.9%) | 8 (44.4%) |
T1DM | 5 (0.8%) | 1 (0.5%) | 0 (0.0%) |
T2DM | 78 (12.0%) | 27 (14.7%) | 0 (0.0%) |
CAD | 29 (4.5%) | 4 (2.2%) | 0 (0.0%) |
Congestive HF | 4 (0.6%) | 0 (0.0%) | 0 (0.0%) |
Hypothyroidism | 21 (3.2%) | 6 (3.3%) | 1 (5.6%) |
VTE | 6 (0.9%) | 1 (0.5%) | 0 (0.0%) |
Autoimmune disease | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) |
Conditions involving regular corticosteroid therapy | 5 (0.78%) | 0 (0.0%) | 0 (0.0%) |
Other | 229 (35.1%) | 62 (33.7%) | 5 (27.8%) |